Trials / Completed
CompletedNCT00100334
Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease
Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- PRAECIS Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, double-blind, inpatient study followed by an outpatient, placebo-controlled, multiple-IV injection evaluation of the safety and tolerability of PPI-1019 in subjects with mild-moderate Alzheimer's disease (AD). The primary objective of the study is to assess the safety of multiple IV injections of PPI-1019 in subjects with mild-moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PPI-1019 (APAN) |
Timeline
- Start date
- 2004-12-01
- Completion
- 2005-08-01
- First posted
- 2004-12-30
- Last updated
- 2006-09-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00100334. Inclusion in this directory is not an endorsement.